
The PhenoSense Entry report results are depicted in an easy-to-understand format that translates directly to treatment planning. A simple net assessment tells you whether your patient is sensitive or resistant to a specific entry inhibitor, such as Fuzeon® (enfuviritide). A fold change bar graph adds detail to your patient's results.
|
|
Download Sample PhenoSense Entry Report |
Fuzeon® is a registered trademark of Roche Laboratories, Inc. and Trimeris, Inc.